Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle Sells 5,630 Shares

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 5,630 shares of the company’s stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $22.38, for a total value of $125,999.40. Following the completion of the sale, the chief financial officer now owns 179,676 shares of the company’s stock, valued at $4,021,148.88. This represents a 3.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Privia Health Group Stock Down 1.2 %

Shares of PRVA stock opened at $21.97 on Friday. Privia Health Group, Inc. has a 12 month low of $15.92 and a 12 month high of $26.04. The company’s fifty day simple moving average is $23.78 and its 200-day simple moving average is $21.29. The firm has a market cap of $2.65 billion, a PE ratio of 219.72, a P/E/G ratio of 3.47 and a beta of 0.85.

Analysts Set New Price Targets

PRVA has been the subject of a number of recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price target on shares of Privia Health Group in a research note on Friday, March 21st. Stephens reiterated an “overweight” rating and issued a $26.00 target price on shares of Privia Health Group in a report on Thursday, January 2nd. JMP Securities set a $29.00 price target on shares of Privia Health Group in a research report on Friday, February 28th. Macquarie started coverage on Privia Health Group in a research note on Monday, December 16th. They set an “outperform” rating and a $25.00 price objective on the stock. Finally, Canaccord Genuity Group boosted their target price on Privia Health Group from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $26.67.

Institutional Investors Weigh In On Privia Health Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its position in shares of Privia Health Group by 6.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,064,224 shares of the company’s stock valued at $19,380,000 after acquiring an additional 65,152 shares during the last quarter. Benjamin Edwards Inc. increased its position in shares of Privia Health Group by 360.7% during the 3rd quarter. Benjamin Edwards Inc. now owns 14,366 shares of the company’s stock worth $262,000 after purchasing an additional 11,248 shares during the last quarter. Centiva Capital LP increased its position in shares of Privia Health Group by 102.6% during the 3rd quarter. Centiva Capital LP now owns 41,614 shares of the company’s stock worth $758,000 after purchasing an additional 21,073 shares during the last quarter. Quarry LP boosted its holdings in shares of Privia Health Group by 344.6% in the 3rd quarter. Quarry LP now owns 3,268 shares of the company’s stock valued at $60,000 after buying an additional 2,533 shares during the last quarter. Finally, Soros Fund Management LLC grew its stake in shares of Privia Health Group by 25.0% in the third quarter. Soros Fund Management LLC now owns 750,000 shares of the company’s stock valued at $13,658,000 after buying an additional 150,000 shares in the last quarter. 94.48% of the stock is owned by institutional investors.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.